The Value of Soluble ST2 in Predicting Cardiorenal Syndrome Type 1 in Acute Myocardial Infarction Patients


  • Ying Hua Department of Cardiology, Affiliated Hospital of Nantong University, 226000 Nantong, Jiangsu, China
  • Wei Zhang Department of Cardiology, Affiliated Hospital of Nantong University, 226000 Nantong, Jiangsu, China
  • Xiaofei Li Department of Cardiology, Affiliated Hospital of Nantong University, 226000 Nantong, Jiangsu, China



acute myocardial infarction, cardiorenal syndrome type 1, soluble growth stimulation gene expression protein 2, estimated glomerular filtration rate, N-terminal pro-B-type natriuretic peptide


Objective: To investigate the predictive value of soluble growth stimulation expressed gene 2 (sST2) for the development of Cardiorenal syndrome type 1 (CRS1) in patients with acute myocardial infarction during hospitalization. Methods: A retrospective study included 202 patients with acute myocardial infarction, divided into the CRS1 group (n = 61) and the Non-CRS1 group (n = 141) by the CRS1 occurrence. A logistic regression analysis was applied to find independent predictors of the CRS1 occurrence during hospitalization. Receiver operating characteristic (ROC) curves were applied to analyze the predictive values of sST2, N-terminal pro-B type natriuretic peptide (NT-proBNP), and estimated glomerular filtration rate (eGFR). Result: The multivariate logistic regression analysis revealed that sST2, NT-proBNP, eGFR, Multivessel coronary artery disease, and diuretic use were independent predictors of the CRS1 occurrence during hospitalization. Application of ROC curve analysis displayed that sST2 had the largest area under the curve (AUC) value of 0.874, sensitivity of 0.770, and specificity of 0.894; sST2, eGFR, and NT-proBNP as combined predictors had an AUC value of 0.908, sensitivity of 0.820, and specificity of 0.908. The ROC curves of sST2 and the combined predictive indices were compared using MedCalc software (version 19.6.3), and no statistically significant difference was found between the two (p = 0.142). The cutoff values of the three indicators were determined by the maximum Youden index. When sST2 ≥61.8 ng/mL, eGFR ≤80.6 mL/min/1.73 m2 and NT-proBNP ≥1525 pg/mL were classified as abnormal range, it was found that more number of abnormal indicators may be more advantageous of risk stratification in CRS1. Conclusions: sST2 can be used as a novel predictor of the CRS1 occurrence in patients with acute myocardial infarction during hospitalization. sST2, eGFR, and NT-proBNP combined may have better predictive value.


Ricci Z, Romagnoli S, Ronco C. Cardiorenal Syndrome. Critical Care Clinics. 2021; 37: 335–347.

Roy AK, Mc Gorrian C, Treacy C, Kavanaugh E, Brennan A, Mahon NG, et al. A Comparison of Traditional and Novel Definitions (RIFLE, AKIN, and KDIGO) of Acute Kidney Injury for the Prediction of Outcomes in Acute Decompensated Heart Failure. Cardiorenal Medicine. 2013; 3: 26–37.

Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Wiviott SD. Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the national cardiovascular data registry. Circulation. 2012; 125: 497–504.

Pimienta González R, Couto Comba P, Rodríguez Esteban M, Alemán Sánchez JJ, Hernández Afonso J, Rodríguez Pérez MDC, et al. Incidence, Mortality and Positive Predictive Value of Type 1 Cardiorenal Syndrome in Acute Coronary Syndrome. PLoS ONE. 2016; 11: e0167166.

Fan PC, Chang CH, Chen YC. Biomarkers for acute cardiorenal syndrome. Nephrology (Carlton, Vic.). 2018; 23 Suppl 4: 68–71.

Goffredo G, Barone R, Di Terlizzi V, Correale M, Brunetti ND, Iacoviello M. Biomarkers in Cardiorenal Syndrome. Journal of Clinical Medicine. 2021; 10: 3433.

Goriki Y, Tanaka A, Nishihira K, Kuriyama N, Shibata Y, Node K. A Novel Prediction Model of Acute Kidney Injury Based on Combined Blood Variables in STEMI. JACC. Asia. 2021; 1: 372–381.

McCarthy CP, Januzzi JL Jr. Soluble ST2 in Heart Failure. Heart Failure Clinics. 2018; 14: 41–48.

Tung YC, Chang CH, Chen YC, Chu PH. Combined biomarker analysis for risk of acute kidney injury in patients with ST-segment elevation myocardial infarction. PLoS ONE. 2015; 10: e0125282.

Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2012; 33: 2569–2619.

Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014; 64: e139–e228.

Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Critical Care (London, England). 2007; 11: R31.

Li J, Sheng X, Cheng D, Wang F, Jian G, Li Y, et al. Is the mean platelet volume a predictive marker of a high in-hospital mortality of acute cardiorenal syndrome patients receiving continuous renal replacement therapy? Medicine. 2018; 97: e11180.

Brar SS, Syros G, Dangas G. Multivessel disease: percutaneous coronary intervention for classic coronary artery bypass grafting indications. Angiology. 2008; 59: 83S–88S.

Choe JC, Cha KS, Ahn J, Park JS, Lee HW, Oh JH, et al. Persistent Renal Dysfunction After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction. Angiology. 2017; 68: 159–167.

Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, Komatsu N, et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. European Journal of Biochemistry. 1999; 264: 397–406.

Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23: 479–490.

Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nature Reviews. Drug Discovery. 2008; 7: 827–840.

Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. The Journal of Clinical Investigation. 1975; 56: 56–64.

Demyanets S, Speidl WS, Tentzeris I, Jarai R, Katsaros KM, Farhan S, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS ONE. 2014; 9: e95055.

Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga SI, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106: 2961–2966.

Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie ANJ, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. The Journal of Clinical Investigation. 2007; 117: 1538–1549.

Dattagupta A, Immaneni S. ST2: Current status. Indian Heart Journal. 2018; 70 Suppl 1: S96–S101.

Griesenauer B, Paczesny S. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Frontiers in Immunology. 2017; 8: 475.

Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clinical Chemistry. 2012; 58: 1673–1681.

Wojtczak-Soska K, Pietrucha T, Sakowicz A, Lelonek M. Soluble ST2 protein in chronic heart failure is independent of traditional factors. Archives of Medical Science: AMS. 2013; 9: 21–26.

Virzì GM, Clementi A, Brocca A, de Cal M, Vescovo G, Granata A, et al. The hemodynamic and nonhemodynamic crosstalk in cardiorenal syndrome type 1. Cardiorenal Medicine. 2014; 4: 103–112.

Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. Journal of the American College of Cardiology. 2007; 50: 607–613.

Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008; 117: 1936–1944.



How to Cite

Hua, Y., Zhang, W. ., & Li, X. . (2023). The Value of Soluble ST2 in Predicting Cardiorenal Syndrome Type 1 in Acute Myocardial Infarction Patients. The Heart Surgery Forum, 26(5), E584-E591.